– USA, MA – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company today announced the appointments of Michele Korfin and Dr. Gilberto Quintero (Ph.D.) to its Board as independent directors, effective May 3, 2022, bringing the board with a majority of independent directors.
“I am pleased to welcome Michele and Gilberto to our Board of Directors, each of whom brings significant experience built over their respective careers working for companies ranging in size and global scale across the healthcare industry. I look forward to leveraging their knowledge and experience from many years working in leadership roles in a variety of areas including operations, commercial, market access, compliance, and regulatory affairs,” said CEO, Gary Gillheeney.
About Michele Korfin
Michele Korfin joined Gamida Cell’s leadership team as COO and CCO in 2020. Before Gamida Cell, Michele served as COO at TYME Technologies. From 2016 until 2018, she was VP of Market Access at Kite Pharma, where she oversaw market access strategy, including payer relations, reimbursement, and government affairs for YESCARTA, the first approved CAR-T therapy in lymphoma. She also worked closely with the manufacturing and supply chain teams at Kite to prepare for FDA approval and commercialization. Before joining Kite, Michele spent more than a decade at Celgene in a variety of key strategic and operational roles, including commercial leadership and oversight of the global development programs for REVLIMID, a therapy approved for patients with certain hematologic malignancies. She also led the Celgene oncology sales force responsible for ABRAXANE, which is now a standard of care in pancreatic cancer.
Michele holds an MBA from Harvard Business School and a B.S. in Pharmacy from Rutgers University. She is also on the Board of Trustees of BioNJ, the organization that represents the biotechnology industry in New Jersey.
About Dr. Gilberto Quintero
Gilberto Quintero, Ph.D. has served as Chief Quality Officer of Global Quality, Regulatory and Compliance at Kimberly-Clark since 2019. Before joining Kimberly-Clark, Gilberto spent more than a decade at Cardinal Health in roles of increasing responsibility most recently serving as Chief Quality and Regulatory Affairs Officer for Pharmaceuticals and Medical Devices. Gilberto’s experience also includes eleven years at Wyeth/Pfizer where he had technical leadership positions in R&D, Quality, and Technical Operations.
Gilberto earned a B.S. in Chemistry from Catholic University, a Ph.D. in Chemistry from Texas A&M University, and an MBA from the University of Tennessee at Chattanooga.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
For more information: https://organogenesis.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
